Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
University of Ottawa
$105,000.00
Pharmacovigilance: Adjuvant Endocrine Therapy and Cardiovascular Events in Post-menopausal Women with Cancer
EF 2009-10
Résumé
This project will attempt to determine if women with cancer are at higher risk for cardiovascular complications following treatment with hormonal therapy. The evaluation will look at over 20 million distinct admissions, emergency department visits, and outpatient cases from 200 health care institutions in the United States. Virtual surveillance of cardiovascular effects will be undertaken in post-menopausal women on hormonal therapy. Pharmaceutical companies, regulatory agencies, health professionals, and consumers all have interest in the identification and prevention of adverse drug reactions to hormonal therapy. Active surveillance of these drugs can lead to the detection of harmful or unexpected side effects in a timely fashion, allowing for appropriate follow-up measures to prevent unnecessary deaths, legal action, and loss of public trust in drug safety. This research will support the proactive post-market drug safety evaluation strategy in by Bill C-51, which has been proposed as a way of enhancing drug safety in Canada.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
206131
Name
Hamel Sophie
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Pharmacovigilance: Adjuvant Endocrine Therapy and Cardiovascular Events in Post-menopausal Women with Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Active Surveillance; Adverse Drug Reactions; Cancer; Cancer Therapy; Cardiovascular Events; Drug Safety And Effectiveness; Endocrine Drugs; Epidemiology; Pharmacovigilance; Population Health
Abstract
This project will attempt to determine if women with cancer are at higher risk for cardiovascular complications following treatment with hormonal therapy. The evaluation will look at over 20 million distinct admissions, emergency department visits, and outpatient cases from 200 health care institutions in the United States. Virtual surveillance of cardiovascular effects will be undertaken in post-menopausal women on hormonal therapy. Pharmaceutical companies, regulatory agencies, health professionals, and consumers all have interest in the identification and prevention of adverse drug reactions to hormonal therapy. Active surveillance of these drugs can lead to the detection of harmful or unexpected side effects in a timely fashion, allowing for appropriate follow-up measures to prevent unnecessary deaths, legal action, and loss of public trust in drug safety. This research will support the proactive post-market drug safety evaluation strategy in by Bill C-51, which has been proposed as a way of enhancing drug safety in Canada.
Competitiondate
200910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Hamel, Sophie
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~